This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Cohen, Ezra
| Item Type | Name |
|
Academic Article
|
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
|
|
Academic Article
|
Current treatment options for metastatic head and neck cancer.
|
|
Academic Article
|
Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
|
|
Academic Article
|
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
|
|
Academic Article
|
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Eruptive cutaneous squamous cell carcinoma and psoriasis: response to cetuximab.
|
|
Academic Article
|
Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.
|
|
Academic Article
|
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
|
|
Academic Article
|
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
|
|
Academic Article
|
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
|
|
Academic Article
|
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
|
|
Academic Article
|
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
|
|
Academic Article
|
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
|
|
Academic Article
|
A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
|
|
Concept
|
Cetuximab
|